ReviewFrontiers in pharmacology2025
Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.Brain and behavior · 2026Article
- Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.European heart journal open · 2026Review
- Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions.Clinical parkinsonism & related disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elderly patients with Type 2 Diabetes Mellitus (T2DM) often experience cognitive dysfunction and gait disorders, which significantly affect their quality of life and daily function. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), known as "wonder drugs for weight loss," have shown potential not only for glycemic control but also for improving cognitive function and gait disturbances. GLP-1RAs may exert their effects through various mechanisms, including promoting neurogenesis and synaptic plasticity in the brain, as well as reducing neuroinflammation, thereby improving cognitive and gait impairments either directly or indirectly. This review aims to explore the role of GLP-1RAs in the treatment of diabetes-related cognitive dysfunction and gait disturbances, as well as their potential mechanisms, providing a theoretical basis for clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.